(R,R’)-4′-Methoxy-1-naphthylfenoterol Targets GPR55-mediated Ligand Internalization and Impairs Cancer Cell Motility.
Abstract
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.
KEYWORDS:
(R)-(+)-[2,3-Dihydro-5-methyl-3-(4–morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin–6-yl]-1-naphthalenylmethanone, (R,R′)-4′-methoxy-1-naphthylfenoterol, (SR141716A,N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride), 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide, 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol, 6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone, AM251, AM630, CBR, CP55,940, Cell motility, Cellular morphology, DIC, Differential Interference Contrast, EGF receptor, EGFR, G-protein coupled receptor, GPR55, L-α-lysophosphatidylinositol, LPI, Ligand internalization, MNF, O-1602, ROI, T1117, Tocrifluor 1117, WIN 55,212-2, [5-methyl-4-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-1,3-benzenediol, beta2 adrenoreceptor, cannabinoid receptor, region of interest, rimonabant, β2-AR
- PMID:
24355564
[PubMed – as supplied by publisher]